DOI QR코드

DOI QR Code

Meta-Analysis of Circulating Endothelial Cells and Circulating Endothelial Progenitor Cells as Prognostic Factors in Lung Cancer

  • Yu, Min (Department of Oncology, The First Affiliated Hospital of Chongqing Medical University) ;
  • Men, Hai-Tao (Department of Oncology, The First Affiliated Hospital of Chongqing Medical University) ;
  • Niu, Zhi-Min (Department of Radiation Oncology, CyberKnife Center, and Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute & Hospital) ;
  • Zhu, Yu-Xi (Department of Oncology, The First Affiliated Hospital of Chongqing Medical University) ;
  • Tan, Ben-Xu (Department of Oncology, The First Affiliated Hospital of Chongqing Medical University) ;
  • Li, Long-Hao (Department of Oncology, The First Affiliated Hospital of Chongqing Medical University) ;
  • Jiang, Juan (Department of Oncology, The First Affiliated Hospital of Chongqing Medical University)
  • Published : 2015.09.02

Abstract

Background: The aim of this study was to analyze the prognostic implications of pretreatment circulating endothelial cells (CECs) and circulating endothelial progenitor cells (CEPCs) for the survival of patients with lung cancer. Materials and Methods: Relevant literature was identified using Medline and EMBASE. Patient clinical characteristics, overall survival (OS) and progression-free survival (PFS) together with CEC and CEPC positive rates before treatment were extracted. STATA 12.0 was used for our analysis and assessment of publication bias. Results: A total of 13 articles (8 for CEC and 5 for CEPC, n=595 and n=244) were pooled for the global meta-analysis. The odds ratio (OR) for OS predicted by pretreatment CECs was 1.641 [0.967, 2.786], while the OR for PFS was 1.168 [0.649, 2.100]. The OR for OS predicted by pretreatment CEPCs was 12.673 [5.274, 30.450], while the OR for PFS was 4.930 [0.931, 26.096]. Subgroup analyses were conducted according to clinical staging. Odds ratio (OR) showed the high level of pretreatment CECs only correlated with the OS of patients with advanced lung cancer (stage III-IV). Conclusions: High counts of CECs seem to be associated only with worse 1-year OS in patients with lung cancer, while high level of pretreatment CEPCs correlate with both worse PFS and OS.

References

  1. Aggarval C, Somaiah N, Simon GR (2010). Biomarkers with predictive and prognostic function in non-small cell lung cancer, ready for prime time? J NCCN, 8, 822-32.
  2. Altman DG (2001). Systematic reviews of evaluations of prognostic variables. BMJ, 323, 224- 8. https://doi.org/10.1136/bmj.323.7306.224
  3. Asahara T, Murohara T, Sullivan A, et al (1997). Isolation of putative progenitor endothelial cells for angiogenesis. Sci, 275, 964-7. https://doi.org/10.1126/science.275.5302.964
  4. Begg CB (1994). Publication bias. 25, 299-409.
  5. Bogos K, Renyi-Vamos F, Dobos J, et al (2009). High VEGFR- 3-positive circulating lymphatic/vascular endothelial progenitor cell level is associated with poor prognosis in human small cell lung cancer. Clin Cancer Res, 15, 1741-6. https://doi.org/10.1158/1078-0432.CCR-08-1372
  6. Bolontrade MF, Zhou RR and Kleinerman ES (2002). Vasculogenesis Plays a Role in the Growth of Ewing’s Sarcoma in Vivo. Clin Cancer Res, 8, 3622-7.
  7. Chu TQ, Ding H, and Garfield DH (2012). Can determination of circulating endothelial cells and serum caspase-cleaved CK18 predict for response andsurvival in patients with advanced non-small-cell lung cancer receiving endostatin and paclitaxel-carboplatinchemotherapy? a retrospective study. J Thorac Oncol, 7, 1781-9. https://doi.org/10.1097/JTO.0b013e3182725fe0
  8. Davidoff AM, Ng CY, Brown P, et al (2001). Bone marrowderived cells contribute to tumor neovasculature and, when modified to express an angiogenesis inhibitor, can restrict tumor growth in mice. Clin Cancer Res, 7, 2870-9.
  9. DerSimonian R, Laird NM (1986). Meta-analysis in clinical trials. Controlled Clinical Trials, 7, 177-88 https://doi.org/10.1016/0197-2456(86)90046-2
  10. Dome B, Timar J, Dobos J, et al (2006). Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lungcancer. Cancer Res, 66, 7341-7. https://doi.org/10.1158/0008-5472.CAN-05-4654
  11. Fleitas T, Martinez-Sales V, Vila V, et al (2012). Circulating endothelial cells and microparticles as prognostic markers in advanced non-small cell lung cancer. PLoS One, 7, 47365. https://doi.org/10.1371/journal.pone.0047365
  12. Fadini GP, Kreutzenberg S, Albiero M, et al (2008). Gender differences in endothelial progenitor cells and cardiovascular risk profile, the role of female estrogens. Arterioscler Thromb Vasc Biolb, 28, 997-1004. https://doi.org/10.1161/ATVBAHA.107.159558
  13. Gao D, Nolan DJ, Mellick AS, et al (2008). Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science, 319, 195-8. https://doi.org/10.1126/science.1150224
  14. Ilie M, Long E, Hofman V, et al (2014). Clinical value of circulating endothelial cells and of soluble CD146 levels in patients undergoing surgery for non-small cell lung cancer. Br J Cancer, 110, 1236-43 https://doi.org/10.1038/bjc.2014.11
  15. Jain RK (2005). Normalization of tumor vasculature, an emerging concept in antiangiogenic therapy. Sci, 307, 58-62. https://doi.org/10.1126/science.1104819
  16. Jemal A, Bray F, Center MM, et al (2009). Global cancer statistics. CA Cancer J Clin, 61, 69.
  17. Kawaishi M, Fujiwara Y, Fukui T, et al (2009). Circulating endothelial cells in non-small cell lung cancer patients treated with carboplatin and paclitaxel. J Thorac Oncol, 4, 208-13 https://doi.org/10.1097/JTO.0b013e318193030d
  18. Mancuso P, Burlini A, Pruneri G, et al (2001). Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood, 97, 3658-61. https://doi.org/10.1182/blood.V97.11.3658
  19. Mancuso P, Antoniotti P, Quarna J, et al (2009). Validation of a standardized method for enumerating circulating endothelial cells and progenitors, flow cytometry and molecular and ultrastructural analyses. Clin Cancer Res, 15, 267-73. https://doi.org/10.1158/1078-0432.CCR-08-0432
  20. Melero-Martin JM, Dudley AC (2011). Concise review,vascular stem cells and tumor angiogenesis. Stem Cells, 29, 163-8. https://doi.org/10.1002/stem.583
  21. Morita R, Sato K, Nakano M,et al (2011). Endothelial progenitor cells are associated with response to chemotherapy in human non-small-cell lung cancer. J Cancer Res Clin Oncol, 137, 1849-57. https://doi.org/10.1007/s00432-011-1043-8
  22. Najjar F, Alammar M, Bachour M, et al (2015). Predictive and prognostic value of circulating endothelial cells in non-small cell lung cancer patients treated withstandard chemotherapy. J Cancer Res Clin Oncol, 141, 119-25. https://doi.org/10.1007/s00432-014-1778-0
  23. Nowak K, Rafat N, Belle S, et al (1998). Circulating endothelial progenitor cells are increased in human lung cancer and correlate with stage of disease. Eur J Cardiothorac Surg, 37, 758-63.
  24. Parmar MK, Torri V, Stewart L, et al (1998). Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med, 17, 2815-34. https://doi.org/10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
  25. Pirro M, Cagini L, Paciullo F, et al (2013). Baseline and post-surgery endothelial progenitor cell levels in patients with early-stage non-small-cell lungcarcinoma, impact on cancer recurrence and survival. Eur J Cardiothorac Surg, 44, 245-52. https://doi.org/10.1093/ejcts/ezt382
  26. Pirro M, Schillaci G, Bagaglia F, et al (2008). Microparticles derived from endothelial progenitor cells in patients at different cardiovascular risk. Atherosclerosis, 197, 757-67. https://doi.org/10.1016/j.atherosclerosis.2007.07.012
  27. Pirro M, Schillaci G, Menecali C, et al (2007). Reduced number of circulating endothelial progenitors and HOXA9 expression in CD34+ cells of hypertensive patients. J Hypertens, 25, 2093-9. https://doi.org/10.1097/HJH.0b013e32828e506d
  28. Pirro M, Schillaci G, Paltriccia R, et al (2006). Increased ratio of CD31+/CD42− microparticles to endothelial progenitors as a novel marker of atherosclerosis in hypercholesterolemia. Arterioscler Thromb Vasc Biol, 26, 2530-5. https://doi.org/10.1161/01.ATV.0000243941.72375.15
  29. Rafii S, Lyden D, Benezra R, et al (2002). Vascular and haematopoietic stem cells, novel targets for anti-angiogenesis therapy? Nat Rev Cancer, 2, 826-35. https://doi.org/10.1038/nrc925
  30. Roodhart JM, Langenberg MH, Vermaat JS, et al (2010). Late release of circulating endothelial cells and endothelial progenitor cells after chemotherapy predicts response and survival in cancer patients. Neoplasia, 12, 87-94. https://doi.org/10.1593/neo.91460
  31. Sakamori Y, Masago K, Ohmori K, et al (2012). Increase in circulating endothelial progenitor cells predicts response in patients with advanced non-small-celllung cancer. Cancer Sci, 103, 1065-70. https://doi.org/10.1111/j.1349-7006.2012.02249.x
  32. Sanchez Hernandez A, Jose Juan O, et al (2015). Vidal Martinez J,Quantification of circulating endothelial cells as a predictor of response to chemotherapy with platinum andpemetrexed in patients with advanced non-squamous non-small cell lung carcinoma. Clin Transl Oncol, 17, 281-8. https://doi.org/10.1007/s12094-014-1223-5
  33. Schillaci G, Rondelli F, Pirro M, et al (2009). Endothelial progenitor cells are mobilized after major laparotomic surgery in patients with cancer. Int J Immunopathol Pharmacol, 22, 1035-41.
  34. Shaked Y, Murohara T, Sullivan A, et al (2005). Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood, 106, 3058-61.
  35. Shantsila E, Lip GY (2008). Circulating endothelial cell in health and disease, how do we best quantify them? J Thromb Haemost, 6, 1021-4. https://doi.org/10.1111/j.1538-7836.2008.02985.x
  36. Stein A, Montens HP, Steppich B, et al (2008). Circulating endothelial progenitor cells decrease in patients after endarterectomy. J Vasc Surg, 48, 1217-22. https://doi.org/10.1016/j.jvs.2008.06.018
  37. Stetler-Stevenson WG and Gavil NV (2014). Normalization of the tumor microenvironment, evidence for tissue inhibitor of metalloproteinase-2 as a cancer therapeutic. Connect Tissue Res, 55, 13-9. https://doi.org/10.3109/03008207.2013.867339
  38. Treat J (2005). Incorporating novel agents with gemcitabinebased treatment of NSCLC. Lung Cancer, 50, 8-9. https://doi.org/10.1016/S0169-5002(05)81551-X
  39. Urbich C, Aicher A, Heeschen C, et al (2005). Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J Mol Cell Cardiol, 39, 733-42. https://doi.org/10.1016/j.yjmcc.2005.07.003
  40. Wang J, Xiao J, Wei X, et al (2013). Circulating endothelial cells and tumor blood volume as predictors in lung cancer. Cancer Sci, 104, 445-52. https://doi.org/10.1111/cas.12097
  41. Willett CG, Boucher Y, Duda DG, et al (2005). Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy, continued experience of a phase I trial in rectal cancer patients. J Clin Oncol, 23, 8136-9. https://doi.org/10.1200/JCO.2005.02.5635
  42. Woywodt A, Blann AD, Kirsch T, et al (2006). Isolation and enumeration of circulating endothelial cells by immunomagnetic isolation, proposal of a definition and a consensus protocol. J Thromb Haemost, 4, 671-7. https://doi.org/10.1111/j.1538-7836.2006.01794.x
  43. Yoon CH, Hur J, Park KW, et al (2005). Synergistic neovascularization by mixed transplantation of early endothelial progenitor cells and late outgrowth endothelial cells, the role of angiogenic cytokines and matrix metalloproteinases. Circulat, 112, 1618-27. https://doi.org/10.1161/CIRCULATIONAHA.104.503433
  44. Yuan DM, Zhang Q, Lv YL, et al (2015). Predictive and prognostic significance of circulating endothelial cells in advanced non-small cell lung cancerpatients.Tumour Biol.
  45. Yue WS, Wang M, Yan GH, et al (2010). Smoking is associated with depletion of circulating endothelial progenitor cells and elevated pulmonary artery systolic pressure in patients with coronary artery disease. Am J Cardiol, 106, 1248-54. https://doi.org/10.1016/j.amjcard.2010.06.045
  46. Shantsila E, Blann AD, Lip GY (2008). Circulating endothelial cells, from bench to clinical practice. J Thromb Haemost, 6, 865-8. https://doi.org/10.1111/j.1538-7836.2008.02918.x

Cited by

  1. Circulating endothelial cells and risk of progression in patients with hepatocellular cancer receiving sorafenib vol.4, pp.2, 2017, https://doi.org/10.2217/hep-2016-0011